Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors

Acquired resistance to imatinib is a significant problem for the clinical management of gastrointestinal stromal tumor (GIST) patients, and second-line small molecules have shown limited efficacy in this setting. We have recently demonstrated that a monoclonal antibody targeting KIT could potentiall...

Descripción completa

Detalles Bibliográficos
Autores principales: Edris, Badreddin, Willingham, Stephen, Weiskopf, Kipp, Volkmer, Anne K, Volkmer, Jens-Peter, Mühlenberg, Thomas, Weissman, Irving L, van de Rijn, Matt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716740/
https://www.ncbi.nlm.nih.gov/pubmed/23894705
http://dx.doi.org/10.4161/onci.24452
_version_ 1782277588776910848
author Edris, Badreddin
Willingham, Stephen
Weiskopf, Kipp
Volkmer, Anne K
Volkmer, Jens-Peter
Mühlenberg, Thomas
Weissman, Irving L
van de Rijn, Matt
author_facet Edris, Badreddin
Willingham, Stephen
Weiskopf, Kipp
Volkmer, Anne K
Volkmer, Jens-Peter
Mühlenberg, Thomas
Weissman, Irving L
van de Rijn, Matt
author_sort Edris, Badreddin
collection PubMed
description Acquired resistance to imatinib is a significant problem for the clinical management of gastrointestinal stromal tumor (GIST) patients, and second-line small molecules have shown limited efficacy in this setting. We have recently demonstrated that a monoclonal antibody targeting KIT could potentially bypass imatinib resistance in preclinical models of GIST.
format Online
Article
Text
id pubmed-3716740
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-37167402013-07-26 Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors Edris, Badreddin Willingham, Stephen Weiskopf, Kipp Volkmer, Anne K Volkmer, Jens-Peter Mühlenberg, Thomas Weissman, Irving L van de Rijn, Matt Oncoimmunology Author's View Acquired resistance to imatinib is a significant problem for the clinical management of gastrointestinal stromal tumor (GIST) patients, and second-line small molecules have shown limited efficacy in this setting. We have recently demonstrated that a monoclonal antibody targeting KIT could potentially bypass imatinib resistance in preclinical models of GIST. Landes Bioscience 2013-06-01 2013-05-14 /pmc/articles/PMC3716740/ /pubmed/23894705 http://dx.doi.org/10.4161/onci.24452 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Edris, Badreddin
Willingham, Stephen
Weiskopf, Kipp
Volkmer, Anne K
Volkmer, Jens-Peter
Mühlenberg, Thomas
Weissman, Irving L
van de Rijn, Matt
Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
title Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
title_full Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
title_fullStr Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
title_full_unstemmed Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
title_short Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
title_sort use of a kit-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716740/
https://www.ncbi.nlm.nih.gov/pubmed/23894705
http://dx.doi.org/10.4161/onci.24452
work_keys_str_mv AT edrisbadreddin useofakitspecificmonoclonalantibodytobypassimatinibresistanceingastrointestinalstromaltumors
AT willinghamstephen useofakitspecificmonoclonalantibodytobypassimatinibresistanceingastrointestinalstromaltumors
AT weiskopfkipp useofakitspecificmonoclonalantibodytobypassimatinibresistanceingastrointestinalstromaltumors
AT volkmerannek useofakitspecificmonoclonalantibodytobypassimatinibresistanceingastrointestinalstromaltumors
AT volkmerjenspeter useofakitspecificmonoclonalantibodytobypassimatinibresistanceingastrointestinalstromaltumors
AT muhlenbergthomas useofakitspecificmonoclonalantibodytobypassimatinibresistanceingastrointestinalstromaltumors
AT weissmanirvingl useofakitspecificmonoclonalantibodytobypassimatinibresistanceingastrointestinalstromaltumors
AT vanderijnmatt useofakitspecificmonoclonalantibodytobypassimatinibresistanceingastrointestinalstromaltumors

Ejemplares similares